Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYL™ (formerly known as sd-rxRNA®) therapeutics can be used as a standalone treatment or in combination with ot...
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYL™ (formerly known as sd-rxRNA®) therapeutics can be used as a standalone treatment or in combination with other modalities. Our development strategy is to tackle different immune escape mechanisms to treat solid tumors.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.